Celebrating the Pharma Industry’s Most Inspirational People and Companies
May 3, 2022
The Medicine Maker is proud to present the Power List 2022 and the inaugural Company of the Year Awards
1 min read
We celebrate the best that the pharma industry has to offer with the 2022 Power List, the inaugural Company of the Year Awards, and the grand winner of the Innovation Awards. Also in this issue, experts share their thoughts on mRNA analysis, Industry 4.0, and flexible cleanrooms. Ukrainian company Enamine explains how drug discovery has been affected by Russia’s Ukraine invasion, and we speak with Novo Nordisk’s Ludovic Helfgott about rare diseases.
May 3, 2022
The Medicine Maker is proud to present the Power List 2022 and the inaugural Company of the Year Awards
1 min read
April 26, 2022
How could the spotlight on mRNA impact the cell and gene field?
1 min read
April 12, 2022
Sitting Down With… Ludovic Helfgott, Executive Vice President, Head of Rare Disease at Novo Nordisk
1 min read
April 5, 2022
How an industry agreement could help bring affordable COVID-19 treatments to low- and middle-income countries
1 min read
March 25, 2022
Why modular or mobile is the best way to go for CMOs
1 min read
March 23, 2022
How can smaller companies navigate scale up and complexity in microbial biomanufacturing?
1 min read
March 21, 2022
A microfluidics-based separation technology aims to overcome common issues in biomanufacturing
1 min read
March 8, 2022
We all know that Industry 4.0 + Pharma = Pharma 4.0 – but are artificial minds and augmented realities changing anything tangible?
1 min read
March 7, 2022
When Ed Griffen of MedChemica first made contact with Enamine, it was to collaborate on the Drugs for Neglected Diseases initiative’s COVID Moonshot project. Now, he’s communicating with colleagues in a warzone.
1 min read
February 21, 2022
mRNA has become a superstar thanks to the success of mRNA-based COVID-19 vaccines, but its importance was known long before the pandemic. Bellal Moghis from the Diagnostics and Genomics Group at Agilent Technologies tells us about the potential of mRNA – and the challenges of working with and analyzing mRNA.
1 min read
False
False